LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Entrepreneur, startup advocate becomes new KC Chamber chair
A prominent Kansas City entrepreneur with some serious startup chops is now serving as the new chair of the Greater Kansas City Chamber of Commerce. Matt Condon, CEO of Bardavon Health Innovations and ARC Physical Therapy, was unanimously voted to serve at the helm of the chamber’s board of directors as its chairman. Condon, 42,…
Video: Healthy workplace culture begins with intention, communication
Editor’s note: This content was sponsored by Mid-Continent Public Library but independently produced by Startland News. Creating a healthy workplace culture must be done early and with intention, said Adrienne Haynes and Dwayne Lewis. To help startups develop a strategic human resource plan, Haynes, managing partner of SEED Law, and Dwayne Lewis, president of Lewis…
From Google to KC, Beth Ellyn McClendon’s advice to startups: Test everything
Don’t fall in love with an idea, Beth Ellyn McClendon said. “Test everything, especially your assumptions, and allow yourself to be persuaded by data,” said McClendon, a seed investor who formerly worked with Google, Android, YouTube, Cisco and Netscape. “Try to remember — tattoo it on your eyelids if you have to – anecdotes are not…
Bodyrite duo cooks meal prep into personal training concept
Don’t just go with the flow at a traditional gym, Jamil Nelson said. Go with Flo. “Treadmills and ellipticals are pretty archaic to us,” said Nelson — or “Mr. Bodyrite” to his wife, Florese. “A jump rope is way better because it’s going to blow up your heart rate.” Modern workouts are all about functional,…